Department of Obstetrics and Gynecology, The Affiliated Nanping First Hospital of Fujian Medical University, Nanping 353000, China.
Department of Gynecology, The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China.
Cell Mol Biol (Noisy-le-grand). 2022 Feb 4;67(5):57-63. doi: 10.14715/cmb/2021.67.5.8.
Insulin resistance and hyperandrogenism are the leading causes of polycystic ovary syndrome (PCOS). Therefore, it has great significance to study the expression levels of PSA, nesfatin-1, and AMH. To provide some reference for clinical diagnosis and treatment of polycystic ovary syndrome (PCOS), the expression levels of PSA, nesfatin-1, and AMH in serum of patients with polycystic ovary syndrome (PCOS) were investigated. The experimental group consisted of 200 patients with polycystic ovary syndrome treated in Shanghai Huashan Hospital from July 2018 to July 2019. The control group consisted of 150 healthy women without pregnancy. The PSA, nesfatin-1, and AMH levels in serum were detected by chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA). The serum levels of prostate-specific antigen (PSA) and anti-Mullerian hormone (AMH) were 16.53 ± 0.67pg/ml and 10.75 ± 4.02pg/ml in the experimental group (PCOS patients), which were significantly higher than those in the control group (3.27 ± 0.43pg/ml and 5.18 ± 1.84pg/ml, respectively), while the inhibitive factors in the experimental group (1.89 ± 0.99mg/ml) were significantly higher than those in the control group (1.10 ± 0.97mg/ml). There was no significant difference in nesfatin-1. The levels of PSA and nesfatin-1, nesfatin-1, and AMH and the levels of PSA and AMH in patients with polycystic ovary syndrome were positively correlated, and the differences were statistically significant. The levels of PSA, nesfatin-1, and AMH in patients with polycystic ovary syndrome of different ages were different, and the differences were significant and negatively correlated with the age increasing. PSA, nesfatin-1, and AMH levels in patients with polycystic ovary syndrome were significantly different from those in control nonpregnant women. There was a certain correlation between the levels of PSA, nesfatin-1, and AMH, and age. The results have specific clinical reference significance for the diagnosis and treatment of patients with polycystic ovary syndrome.
胰岛素抵抗和高雄激素血症是多囊卵巢综合征（PCOS）的主要原因。因此，研究 PSA、nesfatin-1 和 AMH 的表达水平具有重要意义。为了为多囊卵巢综合征（PCOS）的临床诊断和治疗提供一些参考，本研究检测了多囊卵巢综合征患者（PCOS）血清中的 PSA、nesfatin-1 和 AMH 表达水平。实验组由 200 名 2018 年 7 月至 2019 年 7 月在上海华山医院治疗的多囊卵巢综合征患者组成。对照组由 150 名未怀孕的健康女性组成。通过化学发光免疫分析（CLIA）和酶联免疫吸附测定（ELISA）检测血清中前列腺特异性抗原（PSA）、抗苗勒管激素（AMH）和 nesfatin-1 的水平。实验组（PCOS 患者）血清中前列腺特异性抗原（PSA）和抗苗勒管激素（AMH）水平分别为 16.53±0.67pg/ml 和 10.75±4.02pg/ml，明显高于对照组（分别为 3.27±0.43pg/ml 和 5.18±1.84pg/ml），而实验组抑制因子（1.89±0.99mg/ml）明显高于对照组（1.10±0.97mg/ml）。nesfatin-1 无明显差异。多囊卵巢综合征患者 PSA 和 nesfatin-1、nesfatin-1 和 AMH 水平呈正相关，差异有统计学意义。不同年龄多囊卵巢综合征患者 PSA、nesfatin-1、AMH 水平不同，差异有统计学意义，且随年龄增长呈负相关。多囊卵巢综合征患者 PSA、nesfatin-1、AMH 水平与对照组非妊娠女性明显不同。PSA、nesfatin-1、AMH 水平与年龄有一定相关性。结果对多囊卵巢综合征患者的诊断和治疗具有特定的临床参考意义。
